Fundraising FoxSofinnova Partners — 2025 Investments
15 investments dated 2025 · listed companies and verified rows first · show all
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMai-Britt Zocca(CEO)in
Co-investorsMonograph Capital PartnersForbion
Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development.
AI & Machine LearningBiotechDeep Tech
Marty BurkeBartosz GrzybowskiMichael Foley(CEO)inJana Jensen(COO)in
Co-investorsKhosla VenturesCornucopian Capital ManagementDeerfield Management CompanyIllinois Ventures
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)inDaniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsBroadview VenturesApollo Health Ventures+ND Capital4see VenturesLifelinkHumboldt
NanoPhoria is a life sciences company that raised an €83.5 million Series A round.
BiotechDeep TechMedical Devices
Daniele CatalucciinMichele IafiscoAlessio AlognaClaudio De Lucain
Co-investorsXGEN VentureCDP Venture CapitalEuropean Innovation Council Fund
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Seth Harrison(Director)Zack Scott(Director)in
Board seatAntoine Papiernik· per SEC Form D
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatMaina Bhaman· per SEC Form D
Co-investorsAgent CapitalGimvLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.+5 more
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsBioqube VenturesHadean VenturesInnovestor VenturesM Ventures4BIO Capital
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
DBV Technologies develops the VIASKIN® patch, a non-invasive, skin-based immunotherapy technology for treating food allergies and other immunological disorders.
BiotechDigital HealthHealthtechMedical DevicesChâtillon, FR
Pharis Mohideen(Executive Officer)inDaniel Tasse(Executive Officer, Director)inVirginie Boucinha(Executive Officer)in
BoardMailys Ferrere(Director)Michael Goller(Director)Ravi Madduri Rao(Director)
Co-investorsCapDecisif ManagementKarista
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly Capital5AM VenturesAgent Capital+8 more
Forth Therapeutics is an Edinburgh/Cambridge-based biotech spinout from the University of Edinburgh developing precision, omics-driven therapeutics to halt or reverse fibrosis across multiple organ systems.
Co-investorsOld College Capital
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsGilmartin Capital LLCTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst Investors+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsABS Capital PartnersBlue Haven InitiativeFuture Positive CapitalGalvanize Climate SolutionsAlly Bridge GroupFidelity Investments+5 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundEQTEQT Life SciencesForbion+3 more
OneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development.
AI & Machine LearningBiotechDigital HealthMedical DevicesParis, FR
Céline Vallot(Co-founder & CSO)in
Co-investorsBlast.ClubGalion.exeKima VenturesPolytechnique VenturesInvusREDMILE
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.